Canaccord Genuity Downgrades Neoleukin Therapeutics (NLTX) to Hold
Tweet
Share
E-mailGet Alerts NLTX Hot Sheet
Price: $3.49 --0%
Rating Summary:
2 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 17
Rating Summary:
2 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 17
Join SI Premium – FREE
Canaccord Genuity analyst William Maughan downgraded Neoleukin Therapeutics (NASDAQ: NLTX) from Buy to Hold with a price target of $1.00 (from $10.00).
For an analyst ratings summary and ratings history on Neoleukin Therapeutics click here. For more ratings news on Neoleukin Therapeutics click here.
Shares of Neoleukin Therapeutics closed at $0.53 yesterday.
You May Also Be Interested In
- Gemini Space Station (GEMI) PT Lowered to $7 at Mizuho
- BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
- SPC Global Holdings (SPG:AU) PT Lowered to AUD0.14 at Canaccord
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
